Prostate Cancer News on BioPortfolio

InSightec raises $150mm in Series E round prior to planned IPO

In the largest latestage round by an Israeli device company to date InSightec Ltd. magnetic resonance imagingguided focused ultrasound surgery MRgFUS raised $150mm in a Series F round led by Koch Disruptive Technologies an investment group of the diversifi...

ESSA Pharma closes $26mm private placement

ESSA Pharma Inc. oncology therapeutics grossed $26mm through a twotranche private placement. The company sold a total of 82.5mm common shares and 43.8mm prefunded warrants all at $0.20 apiece a 20 discount to the share price when the financing was first an...

US sued by army vet after discovering abandoned scalpel in his pelvis

Body A 61yearold ArmyÂveteranÂhas recently experienced anÂunsettlingÂreallifeÂgame of "Operation" that has turned into a legal battle with the U.S.ÂÂAccording to a recent article byÂMassLive.comÂGlenford TurnerÂfiledÂa lawsuit Jan. 11 after find...

US court invalidates key patent on J&J's Zytiga

US generic competition for Johnson & Johnsons J&J Zytiga abiraterone prostate cancer drug has moved a step closer after a court invalidated a key patent.J&J has said it will appeal against the decision of the Inter Partes review...

TissuePixelation Chip Measures Spatial RNA Expression in Tumor Samples

Scientists have developed a microchipbased RNA analysis technology that can directly measure gene expression spatially across samples of cancer tissue within just a couple of hours. The chips developers led by Rashid Bashir Ph.D. and Farhad Kosari Ph.D. at...

U.S. court invalidates J&J cancer drug patent hitting UK's BTG

NEW YORK Reuters A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc .

U.S. court invalidates patent on J&J cancer drug Zytiga

NEW YORK Reuters A U.S. administrative court on Wednesday invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga bringing rivals closer to selling generic versions.

Pages